Factors for decision making
The searches performed for the evidence review found no evidence to determine if there is any increased risk of developing COVID-19 due to acute use of NSAIDs, or if acute use of NSAIDs can lead to an increased risk of developing more severe symptoms of COVID-19. Therefore, with the agreement of NHS England, indirect evidence relating to the acute use of NSAIDs for other acute respiratory tract infections was summarised. Formal searches and critical appraisal were not conducted for this extension to the original question.
Concerns over using NSAIDs for COVID-19 were raised by the French Health Ministry after 4 people with COVID-19 and no underlying health problems reportedly developed serious symptoms after using these medicines (Day 2020). On 14 March 2020, the French Health Minister issued advice to avoid using NSAIDs for COVID-19 based on a 2019 evaluation by the French National Agency for Medicines and Health Products Safety, which suggested that infection due to chickenpox (varicella) and some bacterial infections could be made worse by ibuprofen and ketoprofen.
On 18 March 2020, the EMA issued a press release stating there is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID‑19. The EMA is monitoring the situation closely and will review any new information that becomes available on this issue in the context of the pandemic.
A CEBM review on NSAIDs in acute respiratory infection (not including COVID-19) concluded that NSAIDs do not significantly reduce total symptoms or duration of respiratory infections. Also, there are long-standing and well-recognised gastrointestinal and renal safety concerns with all NSAIDs, and evidence confirming an increased risk of cardiovascular events with many NSAIDs, including COX-2 inhibitors and some traditional NSAIDs such as diclofenac and high-dose ibuprofen (2,400 mg daily or more).
The CEBM advises that there is a need for caution when using NSAIDs for acute respiratory infections. Pre-existing medications and conditions need to be considered when deciding whether to use NSAIDs for symptomatic acute respiratory infections. Clinicians should follow advice in the BNF and the NICE clinical knowledge summary on issues around prescribing NSAIDs. When considering an NSAID, individual risk factors for adverse effects should be taken into account, including any contraindications, drug interactions, medical history, and any monitoring requirements. The lowest effective dose of an NSAID should be used for the shortest period required to control symptoms and the need for long-term treatment should be reviewed periodically. The MHRA advises that naproxen and low-dose ibuprofen (up to 1,200 mg per day) are considered to have the most favourable thrombotic cardiovascular safety profiles of all NSAIDs.
The EMA advises that, when starting treatment for fever or pain in COVID-19, patients and healthcare professionals should consider all available treatment options, including paracetamol and NSAIDs. Each medicine has its own benefits and risks which are reflected in its product information, and which should be considered along with EU national treatment guidelines, most of which recommend paracetamol as a first treatment option for fever or pain. In line with EU national treatment guidelines, patients and healthcare professionals can continue using NSAIDs (like ibuprofen) as per the approved product information. Current advice includes that these medicines are used at the lowest effective dose for the shortest possible period. Patients who have any questions should speak to their doctor or pharmacist. There is currently no reason for patients taking ibuprofen to interrupt their treatment. This is particularly important for patients taking ibuprofen or other NSAIDs for chronic diseases.
At this time, policy decisions on whether NSAIDs should be used for treating symptoms of COVID-19 will need to take into account data extrapolated from studies involving the use of NSAIDs for other acute respiratory tract infections, together with pharmacoepidemiological studies.
See the full evidence review for more information.
Commissioned by NHS England.